147 related articles for article (PubMed ID: 30662800)
1. Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.
Ji M; Li Z; Lin Z; Chen L
Am J Cancer Res; 2018; 8(12):2402-2418. PubMed ID: 30662800
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer.
Li Z; Quan C; Li W; Ji M
Pathol Res Pract; 2023 Dec; 252():154938. PubMed ID: 37989076
[TBL] [Abstract][Full Text] [Related]
4. CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells.
Li H; Cui R; Ji M; Jin SY
Leuk Res; 2021 Jul; 106():106575. PubMed ID: 33878513
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells.
Moertl S; Payer S; Kell R; Winkler K; Anastasov N; Atkinson MJ
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269745
[TBL] [Abstract][Full Text] [Related]
6. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
[TBL] [Abstract][Full Text] [Related]
7. Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
Kotian S; Zhang L; Boufraqech M; Gaskins K; Gara SK; Quezado M; Nilubol N; Kebebew E
Clin Cancer Res; 2017 Sep; 23(17):5044-5054. PubMed ID: 28600475
[No Abstract] [Full Text] [Related]
8. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
Wang Y; Wen J; Sun X; Sun Y; Liu Y; Cheng X; Wu W; Liu Q; Ren F
Cancer Chemother Pharmacol; 2024 Apr; 93(4):295-306. PubMed ID: 37938423
[TBL] [Abstract][Full Text] [Related]
9. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
11. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer.
Jian Z; Han Y; Zhang W; Li C; Guo W; Feng X; Li B; Li H
Cell Biosci; 2022 Aug; 12(1):135. PubMed ID: 35989326
[TBL] [Abstract][Full Text] [Related]
13. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
14. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
Sun H; Mediwala SN; Szafran AT; Mancini MA; Marcelli M
Horm Cancer; 2016 Jun; 7(3):196-210. PubMed ID: 26957440
[TBL] [Abstract][Full Text] [Related]
15. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
16. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
[TBL] [Abstract][Full Text] [Related]
17. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
[TBL] [Abstract][Full Text] [Related]
18. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth.
Chilamakuri R; Agarwal S
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205815
[TBL] [Abstract][Full Text] [Related]
20. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]